NovaBay Pharmaceuticals Announces Significant Orders for DERMAdoctor’s Top-Selling Kakadu C Anti-Aging Serum ahead of the Holiday Season
NovaBay Pharmaceuticals (NBY) has announced substantial orders for its popular DERMAdoctor Kakadu C 20% Vitamin C Serum, especially timed for the holiday season. CEO Justin Hall indicated these orders are expected to boost revenue for the third and fourth quarters of 2022. The serum, containing stabilized vitamin C sourced from Kakadu plums in Australia, is recognized for its skin-brightening properties. DERMAdoctor products are sold through major retailers and online platforms, enhancing the company's market reach and potential growth.
- Significant orders for DERMAdoctor Kakadu C serum expected to increase revenue in Q3 and Q4 2022.
- Kakadu C serum is marketed as a best-seller due to its effective formulation and popularity.
- None.
“We are excited to share that one of our best-selling products, DERMAdoctor Kakadu C serum, continues its popularity this year with several large orders just in time for the holiday season,” said
Best-selling, antioxidant-rich Kakadu C serum helps to visibly brighten and even skin tone while also improving the appearance of skin elasticity, fine lines and wrinkles. This clinical-strength serum features
The Kakadu C collection was formulated by NovaBay Chief Product Officer,
About
NovaBay Pharmaceuticals Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our business strategies, ability to complete certain financing transactions, current and future product offerings, marketing efforts, and any future revenue that may result from selling such products, as well as generally the Company’s expected future financial results (and ability to continue as a going concern) and the impact of a reverse stock split. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings with the
Socialize and Stay Informed on NovaBay’s Progress
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website
Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com
Avenova.com
DERMAdoctor Purchasing Information
For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20221018005510/en/
NovaBay Contact
Chief Executive Officer and General Counsel
510-899-8800
jhall@novabay.com
Investor Contact
LHA Investor Relations
310-691-7100
jcain@lhai.com
Source:
FAQ
What recent orders did NovaBay Pharmaceuticals announce for NBY?
How will the new orders impact NovaBay's revenue for NBY?
What is the key ingredient of the Kakadu C serum offered by NovaBay (NBY)?